Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, Citogen Partner on Services in Spain, Southern Europe

NEW YORK – SomaLogic said on Monday that it has partnered with Citogen to offer the SomaScan assay in Spain and Southern Europe.

Under the terms of the agreement, Zaragoza, Spain-based Citogen will establish a site authorized by SomaLogic in that country and will provide the SomaScan assay to customers in Southern Europe.

"Spain's established network of research centers [and] universities, and its growing number of biotech companies create great potential for expansion of our proteomics platform, which offers these researchers reliable throughput, reproducibility, high sensitivity, and dynamic range," SomaLogic CEO Adam Taich said in a statement. "The Citogen laboratory has the ability to expand the reach of the SomaScan Platform in Europe and we are pleased to be working with this extraordinary research organization to provide their life sciences customers the technology and innovation that will propel their scientific endeavors forward."

Citogen is the latest SomaLogic-authorized site, joining Group 42 Healthcare in the Middle EastBiostar in ChinaMolecular Genomics in Singapore, and FonesLife in Japan.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.